Anavex Life Sciences Corp (AVXL)

[JPG77]

On Sept 28, Anavex announced that patient "enrollment" for Phase 2a had been completed, which implies the last patients to enroll would not have completed 2a until mid-to-late Oct, which is consistent with your observation. Thanks for keeping us accurate.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that patient enrollment for the Phase 2a clinical trial of ANAVEX 2-73 has been completed ahead of schedule.